Hjem › Multipelt myelom › Minnesota › Rochester
Multipelt myelom kliniske forsøg i Rochester, MN
24 studier for Multipelt myelom søger deltagere på steder i og omkring Rochester (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Rekrutterer
- Mayo Clinic in Rochester, Rochester
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
RekruttererObservationsstudie
- Mayo Clinic in Rochester, Rochester
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Mayo Clinic, Rochester
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Mayo Clinic Rochester, Rochester
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
RekruttererFase 3
- Mayo Clinic, Rochester
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruttererFase 4
- Mayo Clinic Rochester, Rochester
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RekruttererFase 2/3
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Mayo Clinic in Rochester, Rochester
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Mayo Clinic in Rochester, Minnesota, Rochester
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Mayo Clinic Rochester, Rochester
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Mayo Clinic in Rochester, Rochester
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekruttererFase 3
- Mayo Clinic in Rochester, Rochester
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- Mayo Clinic - Transplant Center - Rochester, Rochester
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, Rochester
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RekruttererFase 2
- Mayo Clinic - Minnesota, Rochester
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
RekruttererFase 1
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Mayo Clinic - Rochester /ID# 251164, Rochester
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RekruttererFase 1
- Mayo Clinic, Rochester
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
RekruttererFase 1/2
- Mayo Clinic in Rochester, Rochester
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RekruttererFase 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RekruttererFase 1
- Mayo Clinic in Rochester, Rochester
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Rekrutterer
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
- Mayo Clinic, Rochester
Family Study of Lymphoproliferative Disorders
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
- Mayo Clinic, Rochester
Multipelt myelom forsøg i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
- Seattle, WA22 studier
Andre studier i Rochester
- Brystkræft42 studier
- Ikke-småcellet lungecancer37 studier
- Metastatisk cancer31 studier
- Kræft (alle typer)30 studier
- Colorektal kræft29 studier
- Ægstockræft29 studier
- Prostatakræft22 studier
- Hjertesvigt22 studier
- Bugspytkirtelkræft22 studier
- Lungecancer20 studier
- Livmoderslimhindekræft20 studier
- Kronisk lymfatisk leukæmi19 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.